The ASGR1 Knockout KYSE-150 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of the KYSE-150 esophageal squamous cell carcinoma line with targeted disruption of the ASGR1 gene. This loss-of-function model enables studies on asialoglycoprotein receptor 1 in cancer glycobiology. The polyclonal format preserves cell population heterogeneity for robust functional assays.
KYSE-150 is a human esophageal squamous cell carcinoma line derived from a poorly differentiated tumor, widely used to investigate molecular mechanisms of esophageal carcinogenesis. Its epithelial origin and genetic background provide a relevant host for exploring glycoprotein metabolism in cancer.
The ASGR1 gene product is the major subunit of the asialoglycoprotein receptor, a transmembrane C-type lectin that heterodimerizes with ASGR2 on the cell surface. This receptor specifically recognizes and binds terminal galactose or N-acetylgalactosamine residues exposed on desialylated glycoproteins, initiating clathrin-coated pit formation via interaction with the AP2 complex (including AP2B1). Internalized receptor-ligand complexes traffic to lysosomes marked by LAMP1, where the cargo is degraded by lysosomal hydrolases. ASGR1 expression is controlled by the liver-enriched transcription factors HNF4A, CEBPA, and FOXA2, ensuring tissue-specific regulation. Downstream of ASGR1, endocytic trafficking components and lysosomal enzymes complete the clearance pathway. Knockout of ASGR1 abolishes this receptor-mediated uptake, leading to accumulation of asialylated glycoproteins in the extracellular milieu and potential remodeling of the cell-surface glycocalyx.
In the KYSE-150 esophageal squamous cell carcinoma background, ASGR1 knockout provides a unique opportunity to study ectopic receptor function in non-hepatic malignancy. Although primarily a liver clearance receptor, ASGR1 expression in esophageal tumors may modulate cell-cell adhesion, matrix interactions, and growth factor signaling through altered glycoprotein turnover. Disruption of ASGR1 in this model can reveal how defects in clathrin-mediated endocytosis and lysosomal degradation contribute to aberrant glycosylation patterns commonly observed in cancer, and how these changes influence tumor cell proliferation, migration, and microenvironmental crosstalk.
Experimental workflows with these polyclonal knockout cells can incorporate endocytosis kinetic assays using fluorescent asialoorosomucoid, quantitative western blotting and RT-qPCR to confirm ASGR1 ablation, immunofluorescence and flow cytometry for surface receptor analysis, and cell proliferation or migration assays to assess phenotypic consequences. Glycoproteomic profiling of conditioned media and cell lysates can identify altered glycoprotein signatures, while co-culture systems enable investigation of stromal interactions. This model is well-suited for high-content screening of compounds targeting glycoprotein clearance pathways and for validating the role of ASGR1 in esophageal cancer progression. For additional technical information, please contact Ascent Research.
